Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Urged To Watch And Wait For US/China Tariff War To Blow Over

Executive Summary

Don’t do anything rash to avoid US tariffs on drug products, ingredients and supplies from China, consultants advise. It would be better to just wait to see if the tariff war blows over.

You may also be interested in...



Trump's Chinese Import Tariff Hike Could Take Toll On Consumer Health Sector

Low margins, limited supplier alternatives leave little room for OTC drug marketers in the US to maneuver as ingredients continue  to be subject to Chinese import tariffs.

Trump's Chinese Import Tariff Hike Could Take Toll On Consumer Health Sector

Low margins, limited supplier alternatives leave little room for OTC drug marketers in the US to maneuver as ingredients continue  to be subject to Chinese import tariffs.

Higher Consumer Health Price Tags Ahead As Chinese Import Tariff Increases

Additional tariffs on Chinese imports of ingredients needed for dietary supplements in addition to active ingredients and excipients used in OTC drugs will increase manufacturers' costs even if they arrange to receive ingredients from firms in the US of other countries. The American Herbal Products Association told USTR that firms impacted by the additional tariff "will be faced with the need to either increase prices and thus risk sales losses, absorb additional costs by reducing profit margins, or discontinue products; each of these options risks economic harm to these companies and job losses to their employees."

Related Content

Topics

UsernamePublicRestriction

Register

PS123517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel